ATTENUATION OF ISCHEMIC MYOCARDIAL INJURY AND DYSFUNCTION BY CARDIAC FIBROBLAST-DERIVED FACTOR(S)
スポンサーリンク
概要
- 論文の詳細を見る
Fibroblasts, the majority of non-cardiomyocytes in the heart, are known to release several kinds of substances such as cytokines and hormones that affect cell and tissue functions. We hypothesized that undefined substance(s) derived from cardiac fibroblasts may have the potential to protect against ischemic myocardium. To assess our hypothesis, using rats, we investigated: 1) the effect of cardiac fibroblast-conditioned medium (CM) on the viability of hypoxic cardiomyocytes in vitro, 2) the effect of CM on left ventricular (LV) function in global ischemia-reperfusion in an ex vivo model, 3) the mechanism underlying cardioprotection by CM. Seventy-two hours after starting a hypoxic culture, the viability of cardiomyocytes was higher (P < 0.05) in the CM treated group (41.4%) compared to the control (20.5%). In Langendorffs preparation, 30 min after ischemia-reperfusion, LV end-diastolic pressure was lower, and LV developed pressure and −LVdP/dt were higher (P < 0.01 or P < 0.05) in the CM group than in the control, although coronary flow did not differ between the two groups. Pretreatment with a protein kinase C inhibitor or a mitochondrial ATP-sensitive K+ channel blocker attenuated these changes of LV function in the CM group. Such cardioprotection was achieved by a fraction of the CM having a molecular weight (MW) > 50,000, but not by that of the CM with a lower MW. In addition, a specific antibody against hepatocyte growth factor (HGF, MW is 84,000) did not reduce the cardioprotection afforded by CM. There may be an unknown cardioprotective substance other than HGF in rats, which mimics ischemic preconditioning and has MW > 50,000.
論文 | ランダム
- アインシュタイン方程式の線形近似法 : 復習と定義 いくつかの公式
- 議題167 新規性及び進歩性の要件を評価するに当っての先行技術開示の現行の基準 (国際会議報告) -- (AIPPIリスボン執行委員報告(1))
- 数字・数字・数字 第1回
- 21世紀における企業の知的財産戦略--製薬企業の一例を中心として (特集 組織化する特許戦略)
- 気になる人たち